Ticagrelor Tablet, Film Coated
Product Images NDC 76282-550

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 76282-550). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exelan Pharmaceuticals, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Figure 1)

This description provides information on the comparison of two treatments, Tio0mg and Clopidogrel, for patients with events. The text includes data on the number of patients with events, Kaplan-Meier survival rates at 12 months, and the number of days from the first study drug dose. It also shows the number of patients at risk for each treatment at different time points. This data can be useful for evaluating the effectiveness of these treatments in terms of patient outcomes over time.*

FDA Label Image

Figure 10 (Figure 10)

This appears to be a statistical report on a clinical trial evaluating the cumulative percentage of patients with events over time in two groups (patients treated with Ticagrelor and patients treated with Clopidogrel). It provides information on the number of patients, events, Kaplan-Meier percentage at 12 months, Hazard Ratio, Confidence Interval, and P-value. The data is presented in a time series format over 360 days from randomization.*

FDA Label Image

Figure 11 (Figure 11)

FDA Label Image

Figure 12 (Figure 12)

FDA Label Image

Figure 13 (Figure 13)

This is a data table showing the results of a study comparing different treatments over time. It includes information on the number of patients experiencing events, Kaplan-Meier estimates at 36 months, hazard ratios, and the number of patients at risk over different days from randomization. The study compares treatments labeled as Ti90 mg, Ti60 mg, and Placebo. The data suggests that event rates differ among the treatments over time, with Ti60 mg and Ti90 mg showing lower rates compared to Placebo. The hazard ratios also indicate potential differences in treatment effectiveness.*

FDA Label Image

Figure 14 (Figure 14)

FDA Label Image

Figure 15 (Figure 15)

FDA Label Image

Figure 16 (Figure 16.jpg)

FDA Label Image

Figure 17 (Figure 17)

This text appears to be a medication schedule showing the dosage of Ticagrelor 90 mg compared to a Placebo treatment. It also includes percentage figures and a timeline from randomization. The document seems to be related to a medical study or treatment plan.*

FDA Label Image

Figure 18 (Figure 18.jpg)

This text provides detailed data on various characteristics of a study population, including demographics, medical history, and drug treatments. It includes details such as age distribution, weight categories, geographic regions of participants, prevalence of medical conditions like diabetes and hypertension, and usage of medications like Ticagrelor and Placebo. The text also lists various percentages related to participant characteristics and outcomes, making it a valuable resource for analyzing the study population.*

FDA Label Image

Figure 2 (Figure 2)

FDA Label Image

Figure 3 (Figure 3)

FDA Label Image

Figure 4 (Figure 4)

FDA Label Image

Figure 5 (Figure 5)

FDA Label Image

Figure 6 (Figure 6)

FDA Label Image

Figure 7 (Figure 7)

This information provides details on intrinsic factors that may impact the effects of Ticagrelor AR-C1249100 in individuals. It includes factors such as age (18-45 years, >65), gender (female, male), ethnicity (Japanese, Caucasian), renal impairment (severe, normal), end stage renal disease on hemodialysis, hepatic impairment, and the corresponding treatment recommendations. The text also mentions mean effect and 90% confidence intervals, alongside a graphical representation related to changes relative to a reference point. This data can be valuable for understanding how certain intrinsic factors may influence the response to Ticagrelor AR-C1249100.*

FDA Label Image

Figure 8 (Figure 8)

This document appears to be providing information on drug interactions involving Ticagrelor ARCI2A910XK and recommendations for interacting drugs such as strong CYP3A inhibitors, moderate CYP3A inhibitors, and potent CYP3A5 inducers. It suggests avoiding concomitant use of certain drugs, provides specific dosing adjustments, and mentions the need for avoiding drug combinations to prevent adverse effects. It also includes details on the dosing adjustments required based on the presence of P-glycoprotein (P-gp) and CYP3A inhibitors. The text mentions specific drugs like Ketoconazole, Diltiazem, Rifampin, Aspirin, Desmopressin, Heparin, Enoxaparin, Cyclosporine, Morphine, and Fentanyl, along with their respective administration details and dose adjustments.*

FDA Label Image

Figure 9 (Figure 9)

This text provides information on the mean effect and dose adjustments of Ticagrelor when taken with various interacting drugs such as Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tobramycin, Digoxin, and Cyclosporine. It indicates whether dose adjustment is required when combining Ticagrelor with these medications. The table shows the recommendations for different doses of Ticagrelor and the interacting drugs, helping healthcare professionals optimize treatment regimens.*

FDA Label Image

Structure (Structure)

FDA Label Image

Ticagrelor Tablets Bottle Of 100 (Ticagrelor Tablets Bottle Of 100.jpg)

This text provides information about Ticagrelor tablets, each containing 90 mg of the active ingredient. It includes instructions for storage, dosage, and dispensing, as well as a warning to keep the medication out of reach of children. The medication guide should be given to each patient. The tablets are manufactured by InvaGen Pharmaceuticals, Inc. for Exelan Pharmaceuticals, Inc.*

FDA Label Image

Ticagrelor Tablets Bottle Of 500 (Ticagrelor Tablets Bottle Of 500.jpg)

This text provides detailed information about a medication called Ticagrelor in the form of tablets, showing the quantity, dosage, storage instructions, manufacturer details, and a warning to keep the medication out of reach of children. The medication guide is to be provided to each patient by the pharmacist. It is recommended to store the tablets at a temperature between 20°C to 25°C with excursions permitted to 15°C to 30°C. Please keep the medication in a tight container with a child-resistant closure as required.*

FDA Label Image

Ticagrelor Tablets Bottle Of 60 (Ticagrelor Tablets Bottle Of 60.jpg)

This is a description of a medication called Ticagrelor in tablet form, with each tablet containing 90 mg of the active ingredient. The text includes instructions for storage, dispensing, dosage information, as well as a warning to keep the medication out of reach of children. The medication is manufactured by InvaGen Pharmaceuticals and distributed by Exelan Pharmaceuticals. It is prescribed for certain medical conditions, and dispensing should be accompanied by providing a Medication Guide to each patient.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.